Loading
Savolitinib is a Chinese-discovered pill that blocks the MET growth signal, approved in China for lung cancers with a MET exon 14 mutation and being tested worldwide with osimertinib.
Discovered by Hutchmed in Shanghai and partnered with AstraZeneca since 2011, savolitinib received conditional NMPA approval in June 2021 for MET exon 14 skipping NSCLC after platinum chemotherapy or in patients unfit for it, the first selective MET inhibitor approved in China; full approval and first-line use followed. In EGFR-mutant NSCLC with MET-driven resistance to osimertinib, the SAVANNAH and SACHI trials support the savolitinib plus osimertinib combination, with a Chinese approval of the combination in 2025 and the global SAFFRON phase 3 continuing. Also studied in papillary renal cell carcinoma and MET-amplified gastric cancer.
Highly selective ATP-competitive inhibitor of MET kinase, active against MET exon 14 skipping mutations and MET amplification. Connects to MET and EGFR.
1.Savolitinib slips into a pocket on MET.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| China | 2021 | MET exon 14 skipping NSCLC after platinum chemotherapy or unfit for chemotherapy (conditional; later full) |
| China | 2025 | With osimertinib in EGFR-mutant NSCLC with MET amplification after EGFR TKI (SACHI) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Savolitinib" OR ABSTRACT:"Savolitinib" OR TITLE:"Orpathys" OR ABSTRACT:"Orpathys" OR TITLE:"HMPL-504" OR ABSTRACT:"HMPL-504" OR TITLE:"AZD6094" OR ABSTRACT:"AZD6094" OR TITLE:"volitinib" OR ABSTRACT:"volitinib") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Savolitinib, not a curated reading list.
Shares RAS / RAF / MEK / ERK (MAPK), EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), EGFR-mutated non-small-cell lung cancer, EGFR, Small-molecule kinase inhibitors and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares EGFR, Lung cancer (all types), Non-small-cell lung cancer and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.